These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37268999)

  • 1. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort.
    Huang CF; Jang TY; Wu PH; Kuo MC; Yeh ML; Wang CW; Liang PC; Wei YJ; Hsu PY; Huang CI; Hsieh MY; Lin YH; Hsiao HH; Hsu CM; Huang CT; Lee CY; Chen YH; Chen TC; Lin KD; Wang SH; Wang SF; Huang JF; Dai CY; Chuang WL; Yu ML
    Virol J; 2023 Jun; 20(1):112. PubMed ID: 37268999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
    J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
    Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F
    J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.
    Bánki Z; Mateus J; Rössler A; Schäfer H; Bante D; Riepler L; Grifoni A; Sette A; Simon V; Falkensammer B; Ulmer H; Neurauter B; Borena W; ; Krammer F; von Laer D; Weiskopf D; Kimpel J
    EBioMedicine; 2022 Jun; 80():104073. PubMed ID: 35617826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants.
    Asderakis A; Khalid U; Koimtzis G; Ponsford MJ; Szabo L; Chalklin C; Bramhall K; Grant L; Moat SJ; Humphreys IR; Jolles SR
    Transplantation; 2022 Jul; 106(7):1421-1429. PubMed ID: 35283457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vertigo/dizziness following COVID-19 vaccination.
    Yan HY; Young YH
    Am J Otolaryngol; 2023; 44(2):103723. PubMed ID: 36502671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination.
    Yoo J; Kim Y; Cha YM; Lee J; Jeong YJ; Kim SH; Maragakis LL; Lee S
    J Infect Public Health; 2023 Oct; 16(10):1537-1543. PubMed ID: 37562081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis.
    Song YC; Liu SJ; Lee HJ; Liao HC; Liu CT; Wu MY; Yen HR
    J Microbiol Immunol Infect; 2023 Aug; 56(4):705-717. PubMed ID: 37055256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection.
    Serrano L; Algarate S; Herrero-Cortina B; Bueno J; González-Barriga MT; Ducons M; Montero-Marco J; Acha B; Taboada A; Sanz-Burillo P; Yuste C; Benito R;
    J Appl Microbiol; 2022 Sep; 133(3):1969-1974. PubMed ID: 35801660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity.
    Henze L; Braun J; Meyer-Arndt L; Jürchott K; Schlotz M; Michel J; Grossegesse M; Mangold M; Dingeldey M; Kruse B; Holenya P; Mages N; Reimer U; Eckey M; Schnatbaum K; Wenschuh H; Timmermann B; Klein F; Nitsche A; Giesecke-Thiel C; Loyal L; Thiel A
    Front Immunol; 2023; 14():1056525. PubMed ID: 36798117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.